Asset Details
Do you wish to reserve the book?
Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
Do you wish to request the book?
Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
2021
Overview
Cancer patients with low or absent pre-existing anti-tumour immunity (“cold” tumours) respond poorly to treatment with immune checkpoint inhibitors (ICPI). In order to render these patients susceptible to ICPI, initiation of de novo tumour-targeted immune responses is required. This involves triggering of inflammatory signalling, innate immune activation including recruitment and stimulation of dendritic cells (DCs), and ultimately priming of tumour-specific T cells. The ability of tumour localised therapies to trigger these pathways and act as in situ tumour vaccines is being increasingly explored, with the aspiration of developing combination strategies with ICPI that could generate long-lasting responses. In this effort, it is crucial to consider how therapy-induced changes in the tumour microenvironment (TME) act both as immune stimulants but also, in some cases, exacerbate immune resistance mechanisms. Increasingly refined immune monitoring in pre-clinical studies and analysis of on-treatment biopsies from clinical trials have provided insight into therapy-induced biomarkers of response, as well as actionable targets for optimal synergy between localised therapies and ICB. Here, we review studies on the immunomodulatory effects of novel and experimental localised therapies, as well as the re-evaluation of established therapies, such as radiotherapy, as immune adjuvants with a focus on ICPI combinations.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Adjuvants, Immunologic - therapeutic use
/ Animals
/ Antigens
/ Antigens, Neoplasm - immunology
/ Antigens, Neoplasm - radiation effects
/ Biopsy
/ Cancer Vaccines - therapeutic use
/ Dendritic Cells - immunology
/ Drug Screening Assays, Antitumor
/ Herpesvirus 1, Human - physiology
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - therapeutic use
/ Immunity
/ Immunity, Innate - drug effects
/ Immunomodulating Agents - therapeutic use
/ Immunomodulation - drug effects
/ Immunomodulation - radiation effects
/ Ligands
/ Melanoma
/ Mice
/ Patients
/ T-Lymphocyte Subsets - immunology
/ Toxicity
/ Tumor Microenvironment - immunology
/ Tumors
